Related Experiment Video
Updated: Jan 28, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
The relation between PI3K/AKT signalling pathway and cancer
Saeed Noorolyai1, Neda Shajari1, Elham Baghbani1
1Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract:
Phosphatidylinositol 3-kinases (PI3Ks) are crucial coordinators of intracellular signalling in response to the extracellular stimulators. Hyperactivation of PI3K signalling cascades is one among the most ordinary events in human cancers. Focusing on the PI3K pathway remains both a chance and a challenge for cancer therapy. The high recurrence of phosphoinositide 3-kinase (PI3K) pathway adjustments in cancer has led to a surge in the progression of PI3K inhibitors. Recent developments incorporate a re-assessment of the oncogenic mechanisms behind PI3K pathway modifications. Receptor tyrosine kinases upstream of PI3K, the p110a catalytic fractional unit of PI3K, the downstream kinase, AKT, and therefore the negative regulator, PTEN, are all often altered in cancer. In this review, we consider about the phosphoinositide 3-kinases family and mechanisms of PI3K-Akt stimulation in cancer.
Insights
Phosphatidylinositol 3-kinases (PI3K) pathway hyperactivation drives human cancers. This review examines PI3K family members and PI3K-Akt signaling mechanisms, offering insights for targeted cancer therapy development.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Phosphatidylinositol 3-kinases (PI3Ks) are key regulators of intracellular signaling pathways.
- Hyperactivation of PI3K signaling cascades is frequently observed in human cancers, presenting therapeutic challenges and opportunities.
Purpose of the Study:
- To review the phosphoinositide 3-kinases family.
- To explore the mechanisms of PI3K-Akt pathway stimulation in the context of cancer.
Main Methods:
- Literature review of PI3K pathway alterations in cancer.
- Analysis of oncogenic mechanisms involving PI3K, AKT, and PTEN.
Main Results:
- PI3K pathway dysregulation is common in cancer.
- Key components like receptor tyrosine kinases, PI3K's p110a subunit, AKT, and PTEN are frequently altered.
Conclusions:
- Understanding PI3K pathway mechanisms is crucial for developing effective cancer therapies.
- Targeting PI3K inhibitors represents a significant area of research in oncology.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Hedgehog Signaling Pathway
Insulin: The Receptor and Signaling Pathways
IP3/DAG Signaling Pathway

